IN.PACT AV access randomized trial: Japan cohort outcomes through 12 months.

Abstract

There is a lack of adjudicated and prospectively randomized published outcomes on the use of drug-coated balloons (DCB) to treat dysfunctional arteriovenous fistula in Asian patients. This post hoc subgroup analysis of 112 Japanese participants from the global IN.PACT AV Access trial reports outcomes through 12 months. Participants were treated with DCB (n=58) or standard non-coated percutaneous transluminal angioplasty (PTA) balloons (n=54). Outcomes included target lesion primary patency (TLPP), access circuit primary patency, and safety. Through 6 months, TLPP was 86.0% (49/57) in the DCB group and 49.1% (26/53) in the PTA group (p < 0.001). Through 12 months, TLPP was 67.3% (37/55) in the DCB group and 43.4% (23/53) in the PTA group (p=0.013). In this post hoc analysis of Japanese participants from the IN.PACT AV Access trial, participants treated with DCB had higher TLPP through 6 and 12 months compared with PTA.